uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target
I'm PortAI, I can summarize articles.
Patrick Trucchio has reiterated a Buy rating for uniQure, citing promising results from AMT-130's Phase 1/2 trials for Huntington’s disease, which showed significant slowing of disease progression and reduced neurodegeneration biomarkers. The successful primary endpoint and potential for a Biologics License Application in early 2026 enhance the positive outlook. With robust safety data over 36 months, Trucchio sets a $70 price target for uniQure's stock, supported by his strong track record in the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments